|
1
|
Jain RK, di Tomaso E, Duda DG, Loeffler
JS, Sorensen AG and Batchelor TT: Angiogenesis in brain tumours.
Nat Rev Neurosci. 8:610–622. 2007.
|
|
2
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005.
|
|
3
|
Ong BY, Ranganath SH, Lee LY, et al:
Paclitaxel delivery from PLGA foams for controlled release in
post-surgical chemotherapy against glioblastoma multiforme.
Biomaterials. 30:3189–3196. 2009.
|
|
4
|
Genc DB, Canpolat C and Berrak SG:
Clinical features and management of carboplatin-related
hypersensitivity reactions in pediatric low-grade glioma. Support
Care Cancer. 20:385–393. 2012.
|
|
5
|
Pang Z, Feng L, Hua R, et al:
Lactoferrin-conjugated biodegradable polymersome holding
doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol
Pharm. 7:1995–2005. 2010.
|
|
6
|
Pardridge WM: Brain drug development and
brain drug targeting. Pharm Res. 24:1729–1732. 2007.
|
|
7
|
Guerin C, Olivi A, Weingart JD, Lawson HC
and Brem H: Recent advances in brain tumor therapy: local
intracerebral drug delivery by polymers. Invest New Drugs.
22:27–37. 2004.
|
|
8
|
Muthu MS and Feng SS: Theranostic
liposomes for cancer diagnosis and treatment: current development
and pre-clinical success. Expert Opin Drug Deliv. 10:151–155.
2013.
|
|
9
|
Chaudhury A, Das S, Bunte RM and Chiu GN:
Potent therapeutic activity of folate receptor-targeted liposomal
carboplatin in the localized treatment of intraperitoneally grown
human ovarian tumor xenograft. Int J Nanomedicine. 7:739–751.
2012.
|
|
10
|
Rodriguez BL, Li X, Kiguchi K, DiGiovanni
J, Unger EC and Cui Z: Control of solid tumor growth in mice using
EGF receptor-targeted RNA replicase-based plasmid DNA. Nanomedicine
(Lond). 7:475–491. 2012.
|
|
11
|
Tzeng SY and Green JJ: Therapeutic
nanomedicine for brain cancer. Ther Deliv. 4:687–704. 2013.
|
|
12
|
Marelli UK, Rechenmacher F, Sobahi TR,
Mas-Moruno C and Kessler H: Tumor targeting via integrin ligands.
Front Oncol. 3:2222013.
|
|
13
|
Li Q and Xu W: Novel anticancer targets
and drug discovery in post genomic age. Curr Med Chem Anticancer
Agents. 5:53–63. 2005.
|
|
14
|
Bidros DS and Vogelbaum MA: Novel drug
delivery strategies in neuro-oncology. Neurotherapeutics.
6:539–546. 2009.
|
|
15
|
Gao JQ, Lv Q, Li LM, et al: Glioma
targeting and blood-brain barrier penetration by dual-targeting
doxorubincin liposomes. Biomaterials. 34:5628–5639. 2013.
|
|
16
|
Miyata S, Kawabata S, Hiramatsu R, et al:
Computed tomography imaging of transferrin targeting liposomes
encapsulating both boron and iodine contrast agents by
convection-enhanced delivery to F98 rat glioma for boron neutron
capture therapy. Neurosurgery. 68:1380–1387. 2011.
|
|
17
|
Ying X, Wen H, Lu WL, et al:
Dual-targeting daunorubicin liposomes improve the therapeutic
efficacy of brain glioma in animals. J Control Release.
141:183–192. 2010.
|
|
18
|
Kurohane K, Namba Y and Oku N: Liposomes
modified with a synthetic Arg-Gly-Asp mimetic inhibit lung
metastasis of B16BL6 melanoma cells. Life Sci. 68:273–281.
2000.
|
|
19
|
Maeda T and Fujimoto K: A
reduction-triggered delivery by a liposomal carrier possessing
membrane-permeable ligands and a detachable coating. Colloids Surf
B Biointerfaces. 49:15–21. 2006.
|
|
20
|
Yang XJ, Koh CG, Liu SJ, et al:
Transferrin receptor-targeted lipid nanoparticles for delivery of
an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm.
6:221–230. 2009.
|
|
21
|
Chiu SJ, Liu S, Perrotti D, Marcucci G and
Lee RJ: Efficient delivery of a Bcl-2-specific antisense
oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted
liposomes. J Control Release. 112:199–207. 2006.
|
|
22
|
Adam JF, Joubert A, Biston MC, et al:
Prolonged survival of Fischer rats bearing F98 glioma after
iodine-enhanced synchrotron stereotactic radiotherapy. Int J Radiat
Oncol Biol Phys. 64:603–611. 2006.
|
|
23
|
Gu YT, Zhang H and Xue YX: Dexamethasone
enhances adenosine 5′-triphosphate-sensitive potassium channel
expression in the blood-brain tumor barrier in a rat brain tumor
model. Brain Res. 1162:1–8. 2007.
|
|
24
|
Zhang P, Hu L, Yin Q, Feng L and Li Y:
Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for
sequential blood-brain barrier penetration and glioma targeting
therapy. Mol Pharm. 9:1590–1598. 2012.
|
|
25
|
Gidwani M and Singh AV: Nanoparticle
enabled drug delivery across the blood brain barrier: in vivo and
in vitro models, opportunities and challenges. Curr Pharm
Biotechnol. 14:1201–1212. 2014.
|
|
26
|
Torchilin V: Antibody-modified liposomes
for cancer chemotherapy. Expert Opin Drug Deliv. 5:1003–1025.
2008.
|
|
27
|
Gastaldi L, Battaglia L, Peira E, et al:
Solid lipid nanoparticles as vehicles of drugs to the brain:
Current state of the art. Eur J Pharm Biopharm. 87:433–444.
2014.
|
|
28
|
Wohlfart S, Gelperina S and Kreuter J:
Transport of drugs across the blood-brain barrier by nanoparticles.
J Control Release. 161:264–273. 2012.
|
|
29
|
Hu K, Li J, Shen Y, et al:
Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain
delivery: in vitro and in vivo evaluations. J Control Release.
134:55–61. 2009.
|
|
30
|
Farnsworth RH, Lackmann M, Achen MG and
Stacker SA: Vascular remodeling in cancer. Oncogene. 33:3496–3505.
2014.
|
|
31
|
Jiang X, Xin H, Gu J, et al: Solid tumor
penetration by integrin-mediated pegylated poly(trimethylene
carbonate) nanoparticles loaded with paclitaxel. Biomaterials.
34:1739–1746. 2013.
|
|
32
|
Thoma CR, Zimmermann M, Agarkova I, Kelm
JM and Krek W: 3D cell culture systems modeling tumor growth
determinants in cancer target discovery. Adv Drug Deliv Rev.
69–70:29–41. 2014.
|
